Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · 10% owner | December 30, 2024 | January 02, 2025 |
| Aktis Oncology, Inc.AKTS · Entity 4711 | Director | January 12, 2026 | January 13, 2026 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | September 19, 2023 | September 22, 2023 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director · 10% owner | December 03, 2019 | December 13, 2019 |
| Zymeworks Inc.ZYME · Entity 4458 | Director · 10% owner | June 26, 2025 | June 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date December 30, 2024 · Filed January 02, 2025
Jointly reported with EcoR1 Capital, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,860,180 |
Reported balance
After 2024-12-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-30 · Purchase · Acquired 65,184 · Balance 7,860,180 F2: Qualified Fund purchased all of the securities in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3. F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,873,448 |
Reported balance
After 2024-12-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-12-31 · Purchase · Acquired 13,268 · Balance 7,873,448 F5: Qualified Fund purchased all of the securities in this transaction. F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,880,094 |
Reported balance
After 2025-01-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-01-02 · Purchase · Acquired 6,646 · Balance 7,880,094 F7: Qualified Fund purchased all of the securities in this transaction. F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
F2: Qualified Fund purchased all of the securities in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3.
F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock.
F5: Qualified Fund purchased all of the securities in this transaction.
F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock.
F7: Qualified Fund purchased all of the securities in this transaction.
F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock.
Aktis Oncology, Inc.
Report date January 12, 2026 · Filed January 13, 2026
Jointly reported with EcoR1 Capital, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 2,270,879 |
Reported balance
After 2026-01-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-01-12 · Conversion · Acquired 2,270,879 · Balance 2,270,879 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 202,862 |
Reported balance
After 2026-01-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-01-12 · Conversion · Acquired 202,862 · Balance 202,862 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 128,506 |
Reported balance
After 2026-01-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-01-12 · Conversion · Acquired 128,506 · Balance 128,506 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 4,348,658 |
Reported balance
After 2026-01-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-01-12 · Purchase · Acquired 2,077,779 · Balance 4,348,658 F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 347,305 |
Reported balance
After 2026-01-12 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-01-12 · Purchase · Acquired 144,443 · Balance 347,305 F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-12 · Conversion · Disposed 9,913,810 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-12 · Conversion · Disposed 997,299 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-12 · Conversion · Disposed 488,891 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-12 · Conversion · Disposed 2,397,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-12 · Conversion · Disposed 102,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectSee note | 965,190 |
Reported balance
After 2026-01-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-01-12 · Conversion · Acquired 965,190 · Balance 965,190 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectSee Note | 86,222 |
Reported balance
After 2026-01-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-01-12 · Conversion · Acquired 86,222 · Balance 86,222 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.
F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date.
Nuvation Bio Inc.
Report date September 19, 2023 · Filed September 22, 2023 · Amendment
Jointly reported with EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Notes | 12,674,775 |
Last balance in matching sequence
After 2023-09-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-09-19 · Purchase · Acquired 5,143,000 · Balance 12,504,675 F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 2 · 2023-09-20 · Purchase · Acquired 117,100 · Balance 12,621,775 F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 3 · 2023-09-21 · Purchase · Acquired 53,000 · Balance 12,674,775 F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Qualified Fund is the record holder of these securities.
F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.
F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.
F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.
PROTHENA CORP PUBLIC LTD CO
Report date December 03, 2019 · Filed December 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 9,426,640 |
Reported balance
Holding disclosure · report date 2019-12-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,426,640 F1: Mr. Nodelman is the manager and controlling owner of EcoR1 Capital, LLC ("EcoR1"), an investment adviser to private investment funds (the "Funds"). The Funds hold these securities directly for the benefit of their investors, EcoR1 indirectly beneficially owns such securities as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. Mr. Nodelman disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein and disclaims membership in a group with the Funds within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Nodelman is the manager and controlling owner of EcoR1 Capital, LLC ("EcoR1"), an investment adviser to private investment funds (the "Funds"). The Funds hold these securities directly for the benefit of their investors, EcoR1 indirectly beneficially owns such securities as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. Mr. Nodelman disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein and disclaims membership in a group with the Funds within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.
Zymeworks Inc.
Report date June 26, 2025 · Filed June 27, 2025
Jointly reported with EcoR1 Capital, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 22,970,388 |
Reported balance
After 2025-06-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-26 · Other · Acquired 5,086,480 · Balance 22,970,388 F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 22,970,388 |
Reported balance
After 2025-06-26 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-06-26 · Tax withholding · Disposed 41 · Balance 22,970,388 F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Pre-Funded Warrants (right to acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee note | 0 |
Reported balance
After 2025-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-26 · Other · Disposed 5,086,521 · Balance 0 F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction. F6: The pre-funded warrants did not have an expiration date. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants.
F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock.
F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares.
F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction.
F6: The pre-funded warrants did not have an expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Panacea Acquisition Corp. II
Report date April 28, 2023 · Filed May 02, 2023
Jointly reported with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.
F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionClass A Common Stock · Derivative | 86,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 12 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 86,222 Underlying: Common Stock · 86,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F5 · derivative.exercise_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F5 · derivative.expiration_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionClass A Common Stock · Derivative | 965,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 11 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 965,190 Underlying: Common Stock · 965,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F5 · derivative.exercise_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F5 · derivative.expiration_date: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 102,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 10 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 26,942 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 2,397,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 9 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 630,191 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 488,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 8 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 128,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4 · ownership.nature: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 997,299 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 7 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 262,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 9,913,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · derivative · entry 6 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 2,605,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.exercise_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F1 · derivative.expiration_date: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | PurchaseCommon Stock | 144,443 | $18.00 | $2,599,974.00 |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 5 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 347,305 F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | PurchaseCommon Stock | 2,077,779 | $18.00 | $37,400,022.00 |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 4 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 4,348,658 F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 128,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 128,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4 · ownership.nature: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 202,862 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 202,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3 · ownership.nature: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:28 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | ConversionCommon Stock | 2,270,879 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000935836-26-000031 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director NODELMAN OLEG · CIK 0001454385 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 2,270,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2 · ownership.nature: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 17:50 UTC | Zymeworks Inc. ZYME · Entity 4458 | OtherPre-Funded Warrants (right to acquire) · Derivative | 5,086,521 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000935836-25-000438 · ownership.xml · derivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See note Disclosed balance after: 0 Underlying: Common Stock · 5,086,521 shares Expires not disclosed F5 · shares: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction. F6 · derivative.expiration_date: The pre-funded warrants did not have an expiration date. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 17:50 UTC | Zymeworks Inc. ZYME · Entity 4458 | Tax withholdingCommon Stock | 41 | $12.71 | $521.11 |
DisclosureSEC source: 0000935836-25-000438 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 22,970,388 F4 · kind: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares. F3 · balance_after: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 17:50 UTC | Zymeworks Inc. ZYME · Entity 4458 | OtherCommon Stock | 5,086,480 | $0.00 | $508.65 |
DisclosureSEC source: 0000935836-25-000438 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 22,970,388 F2 · shares: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants. F3 · balance_after: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 19, 2025 Filed May 19, 2025 18:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 5,919 | $11.78 | $69,738.25 |
DisclosureSEC source: 0000935836-25-000389 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,883,908 F4 · shares: Qualified Fund purchased 5,550 of the shares purchased in this transaction. F5 · balance_after: After this transaction, Qualified Fund held 16,764,139 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 49,502 | $11.43 | $565,847.46 |
DisclosureSEC source: 0000935836-25-000389 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,877,989 F2 · shares: Qualified Fund purchased 46,405 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,758,589 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 15:17 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 54,760 | $11.52 | $630,818.77 |
DisclosureSEC source: 0000935836-25-000292 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,828,487 F5 · shares: Qualified Fund purchased 51,344 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.5125 to $11.5214, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 16,712,184 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 16, 2025 Filed Apr 18, 2025 15:17 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 73,953 | $11.16 | $825,589.11 |
DisclosureSEC source: 0000935836-25-000292 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,773,727 F2 · shares: Qualified Fund purchased 69,339 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.9823 to $11.2339 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each seperate price within the ranges set forth in this footnote and footnote 6. F4 · balance_after: After this transaction, Qualified Fund held 16,660,840 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 18:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 196,438 | $11.17 | $2,193,799.94 |
DisclosureSEC source: 0000935836-25-000266 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,699,774 F5 · shares: Qualified Fund purchased 184,181 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.9804 to $11.2921, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 16,591,501 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 18:34 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 120,770 | $11.84 | $1,430,170.42 |
DisclosureSEC source: 0000935836-25-000266 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,503,336 F2 · shares: Qualified Fund purchased 113,233 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.8101 to $11.9123 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each seperate price within the ranges set forth in this footnote and footnote 6. F4 · balance_after: After this transaction, Qualified Fund held 16,407,320 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 19:02 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 74,360 | $11.85 | $881,017.28 |
DisclosureSEC source: 0000935836-25-000259 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,382,566 F6 · shares: Qualified Fund purchased 69,720 of the shares purchased in this transaction. F7 · balance_after: After this transaction, Qualified Fund held 16,294,087 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 19:02 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 48,658 | $11.60 | $564,646.90 |
DisclosureSEC source: 0000935836-25-000259 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,308,206 F4 · shares: Qualified Fund purchased 45,622 of the shares purchased in this transaction. F5 · balance_after: After this transaction, Qualified Fund held 16,224,367 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 19:02 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 4,397 | $11.75 | $51,658.15 |
DisclosureSEC source: 0000935836-25-000259 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,259,548 F2 · shares: Qualified Fund purchased 4,129 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,178,745 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 18:53 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 43,848 | $12.24 | $536,857.37 |
DisclosureSEC source: 0000935836-25-000253 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,255,151 F4 · shares: Qualified Fund purchased 41,177 of the shares purchased in this transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.2293 to $12.3537, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F6 · balance_after: After this transaction, Qualified Fund held 16,174,616 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 18:53 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 53,501 | $12.91 | $690,451.81 |
DisclosureSEC source: 0000935836-25-000253 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,211,303 F2 · shares: Qualified Fund purchased 50,243 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,133,439 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 24, 2025 Filed Mar 24, 2025 17:45 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 22,689 | $13.08 | $296,846.99 |
DisclosureSEC source: 0000935836-25-000245 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,157,802 F7 · shares: Qualified Fund purchased 21,307 of the shares purchased in this transaction. F8 · balance_after: After this transaction, Qualified Fund held 16,083,196 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 17:45 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 31,033 | $12.78 | $396,517.95 |
DisclosureSEC source: 0000935836-25-000245 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,135,113 F4 · shares: Qualified Fund purchased 29,143 of the shares purchased in this transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.6895 to $12.9881 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote with the ranges set forth in this footnote. F6 · balance_after: After this transaction, Qualified Fund held 16,061,889 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:45 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 73,476 | $12.93 | $949,883.03 |
DisclosureSEC source: 0000935836-25-000245 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,104,080 F2 · shares: Qualified Fund purchased 69,000 of the shares purchased in this transaction. F3 · balance_after: After this transaction, Qualified Fund held 16,032,746 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 18:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 58,306 | $12.64 | $737,232.73 |
DisclosureSEC source: 0000935836-25-000239 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 17,030,604 F8 · shares: Qualified Fund purchased 54,758 of the shares purchased in this transaction. F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.5029 to $12.7711, inclusive. F10 · balance_after: After this transaction, Qualified Fund held 15,963,746 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 18:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 113,880 | $12.65 | $1,440,855.31 |
DisclosureSEC source: 0000935836-25-000239 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,972,298 F5 · shares: Qualified Fund purchased 106,944 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.3214 to $12.7045, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 15,908,988 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 18:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 56,277 | $12.23 | $688,464.68 |
DisclosureSEC source: 0000935836-25-000239 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,858,418 F2 · shares: Qualified Fund purchased 52,849 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.1287 to $12.2678 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote with the ranges set forth in this footnote. F4 · balance_after: After this transaction, Qualified Fund held 15,802,044 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 19:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 468,356 | $12.48 | $5,847,237.32 |
DisclosureSEC source: 0000935836-25-000225 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,802,141 F8 · shares: Qualified Fund purchased 439,831 of the shares purchased in this transaction. F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.26 to $12.55, inclusive. F10 · balance_after: After this transaction, Qualified Fund held 15,749,195 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 19:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 292,934 | $12.25 | $3,587,826.34 |
DisclosureSEC source: 0000935836-25-000225 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,333,785 F5 · shares: Qualified Fund purchased 275,095 of the shares purchased in this transaction. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.0008 to $12.3728, inclusive. F7 · balance_after: After this transaction, Qualified Fund held 15,309,364 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 19:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | PurchaseCommon Stock | 320,690 | $11.49 | $3,685,850.52 |
DisclosureSEC source: 0000935836-25-000225 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 16,040,851 F2 · shares: Qualified Fund purchased 301,160 of the shares purchased in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.115 to $11.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote with the ranges set forth in this footnote and footnote 6 and 9. F4 · balance_after: After this transaction, Qualified Fund held 15,034,269 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 02, 2025 Filed Jan 2, 2025 18:17 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 6,646 | $12.95 | $86,069.69 |
DisclosureSEC source: 0000935836-25-000008 · ownership.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 7,880,094 F7 · shares: Qualified Fund purchased all of the securities in this transaction. F8 · balance_after: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 18:17 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 13,268 | $12.93 | $171,512.78 |
DisclosureSEC source: 0000935836-25-000008 · ownership.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 7,873,448 F5 · shares: Qualified Fund purchased all of the securities in this transaction. F6 · balance_after: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 18:17 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 65,184 | $12.92 | $842,059.95 |
DisclosureSEC source: 0000935836-25-000008 · ownership.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 7,860,180 F2 · shares: Qualified Fund purchased all of the securities in this transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3. F4 · balance_after: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock. F1 · ownership.nature: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 15:44 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 53,000 | $1.36 | $72,138.30 |
DisclosureSEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,674,775 F5 · date: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 15:44 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 117,100 | $1.36 | $159,490.20 |
DisclosureSEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,621,775 F4 · date: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 15:44 UTC Amendment | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 5,143,000 | $1.26 | $6,460,636.60 |
DisclosureSEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,504,675 F3 · date: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 28, 2023 Filed May 2, 2023 17:15 UTC | Panacea Acquisition Corp. II PANA · Entity 114006 | Disposition to issuerClass A ordinary shares | 545,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026595 · doc4.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F1 · price: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 21, 2023 Filed Sep 21, 2023 20:08 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 53,000 | $1.36 | $72,138.30 |
DisclosureSEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,674,775 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| February 20, 2023 Filed Sep 21, 2023 20:08 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 117,100 | $1.36 | $159,490.20 |
DisclosureSEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,621,775 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| February 19, 2023 Filed Sep 21, 2023 20:08 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 5,143,000 | $1.26 | $6,460,636.60 |
DisclosureSEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director Biotech Opportunity GP, LLC · CIK 0001816370 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Notes Disclosed balance after: 12,504,675 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| May 05, 2022 Filed May 9, 2022 06:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 668,237 | $21.63 | $14,453,966.31 |
DisclosureSEC source: 0001567619-22-009732 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 7,521,024 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: The filing persons (the "Filers") are EcoR1, Oleg Nodelman and Qualified Fund. EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund and Capital Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to beneficially own the securities indirectly as the investment adviser to the Funds, and Mr. Nodelman may be deemed to beneficially own them indirectly as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 05, 2022 Filed May 9, 2022 06:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 668,237 | $21.63 | $14,453,966.31 |
DisclosureSEC source: 0001567619-22-009732 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes Disclosed balance after: 7,521,024 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: The filing persons (the "Filers") are EcoR1, Oleg Nodelman and Qualified Fund. EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund and Capital Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to beneficially own the securities indirectly as the investment adviser to the Funds, and Mr. Nodelman may be deemed to beneficially own them indirectly as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: After this transaction, Qualified Fund held 7,042,903 shares of the Issuer's Common Stock. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 21,758 | $7.69 | $167,229.81 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,169,241 F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 163,268 | $7.69 | $1,254,861.52 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 7,361,675 F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 01:37 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 45,229 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001209191-21-062590 · doc4.xml · derivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,229 Underlying: Class A Common Stock · 45,229 shares Expires 2031-10-28 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (October 29, 2022); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.